In addition, any statements that refer to projections of Arrowhead’s future financial performance, trends in its businesses, or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements represent managements’ current expectations and are inherently uncertain.You should also refer to the discussions under Risk Factors in Arrowhead’s Annual Report on Form 10-K for additional matters to be considered in this regard. Thus actual results may differ materially. Arrowhead undertakes no duty to update any of the forward-looking statements discussed on today’s call. With that said, I’d like to turn the call over to Dr. Christopher Anzalone, President and CEO of the company. Chris? Christopher Anzalone Thanks, Brandi. Good afternoon, everyone, and thank you for joining us on our call today. Fiscal 2010 was a pivotal year for our company from both scientific and corporate standpoints. We are a much different company now than when I spoke with you a year ago, and we have achieved a number of important strategic and operational goals designed to accelerate our broader objectives of assembling a leading portfolio of nanomedicine companies. So what has changed? First and foremost, we reported first ever clinical data proving systemic delivery of siRNA in humans and gene silencing via RNAi. As we have discussed in the past, these breakthrough data are important to both the RNA industry and to our company. Positive gene silencing data are of no value, however, unless coupled with a well-tolerated therapeutic. We reported positive interim safety data from Calando’s Phase 1 clinical trial at the 2010 American Society of Clinical Oncology Meeting or ASCO. We have expanded the breadth of our nanomedicine portfolio by creating a new subsidiary, Ablaris Therapeutics, to address the large obesity markets opportunity and secure an outside capital for its initial funding by increasing our ownership position in our subsidiaries and by initiating partnerships and operations with our earlier stage opportunities.